Overview

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Status:
Completed

Trial end date:
2017-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the impact on tumor progression as evaluated by progression-free survival (PFS) of epoetin alfa plus standard supportive care as compared with standard supportive care alone (packed red blood cell (RBC) transfusions), for treating anemia according to label guidance in patients with metastatic breast cancer receiving standard chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Epoetin Alfa